Selenium and Breast Cancer Chemoprevention
Annual rept. 1 Aug 2004-30 Nov 2005
COLORADO STATE UNIV FORT COLLINS
Pagination or Media Count:
The primary objective of this project is to determine whether selenium supplementation affects candidate markers of breast cancer risk in a cohort of women at elevated risk for breast cancer. The intermediate biomarkers being studied are as follows indicators of oxidative damage to cellular macromolecules such as DNA and lipids, indicators of IGF metabolic status, and cellular indicators of breast cancer risk. The authors proposed a randomized, placebo-controlled, double-blind chemoprevention trial with 150 participants 75 subjects per arm using a placebo tablet or a tablet containing 200 micrograms of high-selenium brewers yeast per day, given for a duration of 1 year. The form and dose of selenium that is being used has been reported to reduce cancer incidence and mortality in lung, prostate, and colon. Blood and urine is being collected at baseline, and after 6 and 12 months of intervention. The feasibility of obtaining breast epithelial cells via nipple aspiration at baseline and at the end of the intervention is being assessed. Plasma selenium and glutathione peroxidase activity are being evaluated in addition to pill counts and self-reports as markers of compliance.
- Anatomy and Physiology
- Medicine and Medical Research
- Food, Food Service and Nutrition